LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Sanofi

Chiusa

50.48 1.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

49.14

Massimo

50.55

Metriche Chiave

By Trading Economics

Entrata

1.4B

1.9B

Vendite

3B

11B

P/E

Media del settore

17.382

51.198

EPS

1.022

Rendimento da dividendi

4.5

Margine di Profitto

17.65

Dipendenti

82,878

EBITDA

2.2B

2.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+25% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.50%

2.40%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-17B

121B

Apertura precedente

48.52

Chiusura precedente

50.48

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Sanofi Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2025, 16:05 UTC

I principali Market Mover

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 giu 2025, 09:17 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 giu 2025, 05:31 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 mag 2025, 12:02 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 mag 2025, 00:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 giu 2025, 13:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 giu 2025, 12:33 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 giu 2025, 10:50 UTC

Acquisizioni, Fusioni, Takeovers

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 giu 2025, 10:05 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 giu 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 giu 2025, 05:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 giu 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 giu 2025, 05:05 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 giu 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 giu 2025, 05:04 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 giu 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Blueprint Medicines Corporation

2 giu 2025, 05:02 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Acquire Blueprint Medicines Corporation

30 mag 2025, 08:58 UTC

Azioni calde

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mag 2025, 08:56 UTC

Discorsi di Mercato

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 mag 2025, 05:03 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 mag 2025, 05:00 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 mag 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mag 2025, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mag 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mag 2025, 23:20 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mag 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

12 mag 2025, 12:07 UTC

Discorsi di Mercato

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 mag 2025, 17:55 UTC

Utili

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

Confronto tra pari

Modifica del prezzo

Sanofi Previsione

Obiettivo di Prezzo

By TipRanks

25% in crescita

Previsioni per 12 mesi

Media 62.2 USD  25%

Alto 67 USD

Basso 56 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

2

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.665 / 52.38Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.